CD9 and cancer: Results using the ExoScreen assay from the same group [22] showed that detection of CD145/CD9 dual positive cancer EVs is possible using 5 μL serum of colorectal cancer patients, and that EVs positive for GPRC5C/CD63 can discriminate pancreatitis patients from stage II pancreatic cancer.